Smith & Nephew restructuring provides potential $750 million war chest
This article was originally published in Clinica
Smith & Nephew, the UK orthopaedics, wound management and endoscopy company, could have as much as £500 million ($750 million) to spend on acquiring new businesses. The company's CEO Chris O'Donnell said that financial restructuring has given S&N a borrowing power that will enable it to add companies at the rate of two or three a year.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.